SOUTH KOREA · OPENDART
AbClon Inc.
앱클론 · 174900 · KOSDAQ · Healthcare · Biotechnology
Score
Not ranked: no net buying on the exchange by an individual insider in the last 180 days.
Insiders' buying price vs the latest close
Insiders paid 54,138.46 KRW a share on average (2 purchase lines, 2 buyers, 2025-11-18 – 2026-04-01). The close on 2026-10-16 was 56.0% below that price.
The latest purchase (2026-04-01) was at 60,000.00 KRW; the close was 60.3% below that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Insider trades on the exchange
Purchases and sales on the exchange in the last 12 months. The filing gives the settlement date; the trade date is two trading days earlier.
Other changes in holdings · 7
Option exercises, grants, new shares, inheritance, gifts, off-exchange trades and trades by companies and funds. Not counted in the score.
| Date | Insider | Role | Reason | Shares | Filing |
|---|---|---|---|---|---|
| 2026-08-01 | Jeong, Byung Seok | Senior managing director | New appointment(+) | 40 | DART ↗ |
| 2026-04-27 | Kim Ki Hyun | Director | Exercise of appraisal rights(+) | 1,033 | DART ↗ |
| 2026-04-27 | Kim Dong-Wook | Director | Exercise of appraisal rights(+) | 1,033 | DART ↗ |
| 2026-01-21 | Kim Ki Hyun | Director | Exercise of appraisal rights(+) | 2,198 | DART ↗ |
| 2026-01-01 | LEE YOUNG HA | Director | New report(+) | 39,925 | DART ↗ |
| 2026-01-01 | Hwang In Sik | Director | New report(+) | 50,000 | DART ↗ |
| 2026-01-01 | Kim Ki Hyun | Director | New report(+) | 5,000 | DART ↗ |